Current Oncology, Free Full-Text

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

Home page Cardio-Oncology

Creative Options, ADT Program, Creative Options

Current Oncology, Free Full-Text

📆 Save the date - West Cancer Center & Research Institute

Current Oncology, Free Full-Text, Skin Tone Construction Paper

Current Oncology, Free Full-Text

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Journal of Clinical Oncology

Current Oncology, Free Full-Text

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

Cancer Support Groups, Counseling, Education & Financial Assistance

Reality TV Star Lacey Wildd -- Busted for Bikini Abuse

This woman with triple Q breast implants has spent over $1 million

Treating Triple-Negative Breast Cancer

This woman with triple Q breast implants has spent over $1 million in plastic surgery

This woman with triple Q breast implants has spent over $1 million in plastic surgery